AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Salesforce seals $1.9 billion cash deal to acquire cloud backup company Own
More news

Pharmaceuticals

20 stories about Pharmaceuticals
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
האקר האקרים סייבר

Cyber attack shuts down Israeli pharma company's distribution

17.06.24|Omer Kabir
Rekah, a prominent local producer of medicines, cosmetics, vitamins, and nutritional supplements, said it is working "to contain the incident, locate and thwart it, and restore compromised systems to operation"
ריצ'רד פרנסיס מנכ"ל טבע

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman
AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
מוסף שבועי 22.2.24 היזמית מיכל צור

"Until there is unity and equality here, Israel has no chance"

22.02.24|Sophie Shulman
At night, serial entrepreneur Michal Tsur doesn’t sleep, worrying about her son fighting in the army. During the day, she is busy with her third startup, Remepy, and dreaming of a new country - the same country for which she took to the streets as one of the leaders of last year’s protest against the judicial reform
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
ריצ'רד פרנסיס מנכ"ל טבע

Teva CEO: Israel’s production capacity has not been affected by the war

08.11.23|Sophie Shulman
The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.
צוות Nucleai מימין לוטן חורב אלירון אמיר אבי ויידמן אלברט אכטרברג

The Israeli startup using spatial biology to provide better cancer treatment

02.01.22|Yafit Ovadia
Nucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions
David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
גלעד רדאי

Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms

28.02.21|Yafit Ovadia
Israeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
מימין תומר קריב ו רן נוסבאום מנהלי קרן פונטיפקס

Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold

12.10.20|Tzally Greenberg
A series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis
קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

What’s behind the timed resurgence of lawsuits against Teva?

28.08.20|Sophie Shulman
The Israeli pharmaceutical giant was hit with three legal blows over the course of a few days
מוסף שבועי 16.4.20 פרופ' רגינה ברזילי

Hitting the Reset Button on Antibiotics

17.04.20|Viki Auslender
As the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment
אסטרהזנקה חברת תרופות מטה בריטניה astrazeneca

Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel

27.11.19|Meir Orbach
Alongside funding, the program will provide Israeli startups with mentorship and training
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
אתר טבע כפר סבא

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

30.07.19|Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
More Articles